GSK and others delist Orange Book patents after FTC targets protections on inhalers and epinephrine injectors

Three phar­ma com­pa­nies have agreed to delist some of the patents chal­lenged by the Fed­er­al Trade Com­mis­sion in No­vem­ber, part of a push by the agency to tar­get prac­tices it claims are lim­it­ing com­pe­ti­tion.

GSK agreed to delist 12 of 14 patents iden­ti­fied by the FTC, plus an ad­di­tion­al five more “in light of evolv­ing poli­cies and de­vel­op­ments in the law re­gard­ing the list­ing of drug-de­vice com­bi­na­tions,” ac­cord­ing to a let­ter sent Thurs­day from law­mak­ers to FDA Com­mis­sion­er Rob Califf, which out­lined the changes.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.